Africa institutional business volatility
Africa anti-malarial business declined ~42% in 9M FY25 due to lower Global Fund procurement; future depends on donor funding, which is uncertain given U.S. policy changes.
high · management_commentary
Ajanta Pharma Limited — Q3 FY25
Ajanta Pharma reported Q3 FY25 revenue of INR 1,146 crore (+4% YoY), with branded generics growing 10% to INR 834 crore.
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
U.S. generic price erosion and launch delays
U.S. generics growth is dependent on new product launches and limited competition; any delays or higher-than-expected price erosion could impact growth.
medium · analyst_questionMargin pressure from new therapy investments
Entry into gynecology and nephrology in India and CNS in Asia will increase SG&A and personnel costs, potentially pressuring near-term margins.
medium · data_observationTax rate increase in FY27
Management indicated tax rate may rise from 24% to ~25% in FY27 as some exemptions expire, impacting net profitability.
low · management_commentary